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Background. The aim of the study was to evaluate the clinical and imaging features of extraskeletal myxoid chon-
drosarcoma (EMC) including initial presentation, recurrence, and metastases.
Patients and methods. In this institutional review board-approved retrospective study, imaging features of 13 pa-
tients with pathologically proven EMC seen from August 1995 to December 2011 were analyzed. The group included 
3 women and 10 men and the mean age was 54 years (range 29-73 years). Imaging studies were evaluated by two 
radiologists in consensus. Location, size, and imaging features of primary tumors were recorded as well as the pres-
ence of recurrent disease and location of metastases. 
Results. Among 13 patients, 3 died during the timeframe of this study. Nine patients had primary tumor in the lower 
extremity, and average tumor size was 9.3 cm (range 3.3-18 cm). On MRI, primary tumors were hyperintense on T2, 
isointense to muscle on T1, and demonstrated peripheral/septal enhancement. Three patients had local recurrence 
and 12 had metastatic disease, with lung involvement being the most common. Tumor density on contrast enhanced 
CT ranged from 8.2 to 82.9 Hounsfield unit (HU). FDG-PET/CT imaging was performed in 3 patients. One patient had no 
FDG avid disease and 2 patients had metastatic disease with standard uptake values (SUV) of 2.8 and 7.4. The patient 
with intense FDG uptake demonstrated more solid appearing tumor burden and had the shortest survival.
Conclusions. EMC is a rare tumor that often occurs in the lower extremities and frequently metastasizes to the lungs. 
Increased tumor density and increased FDG uptake may be related to more aggressive disease.
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Introduction
Extraskeletal myxoid chondrosarcoma (EMC) is 
a rare soft tissue tumor characterized by uniform 
spindle cells arranged in a reticular growth pat-
tern in abundant myxoid stoma.1,2 Considered to 
be slow growing, it generally arises in the deep 
soft tissues of the proximal limbs but several un-
usual sites such as the scrotum and finger have 
been documented.3-5 The typical appearance is of 
a lobulated mass composed of gelatinous nodules 
with internal fibrous septa.6 Although originally 
believed to be a variant of chondrosarcoma, the 
World Health organization has classified it as a 
tumor of uncertain differentiation due to its lack 
of cartilaginous differentiation.3 Additionally, 
cytogenetic studies have shown that EMC is a 
unique entity with a reciprocal translocation, 
t(9;22) (q22;q12), not seen in conventional skel-
etal chondrosarcoma.7-12 Despite being considered 
a low grade sarcoma with a prolonged clinical 
course, extraskeletal myxoid chondrosarcoma has 
been shown to have a high rate of local recurrence 
and metastasis.13Radiol Oncol 2014; 48(3): 235-242.
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The literature documenting the imaging fea-
tures of extraskeletal myxoid chondrosarcoma is 
limited. With rare exception, most of the radiol-
ogy literature has consisted of case reports or has 
been based on a single imaging modality with little 
evaluation of the imaging spectrum.3-6 The purpose 
of this study was to evaluate the imaging features 
of primary extraskeletal myxoid chondrosarcoma, 
as well as the imaging characteristics of local recur-
rence and metastatic disease. 
Patients and methods
Patients
In this institutional review board-approved retro-
spective study, the electronic medical records of 13 
patients with pathologically proven extraskeletal 
myxoid chondrosarcoma who were evaluated at 
our institution from August 1995 to December 2011 
were reviewed. No patients with pathologically 
proved EMC were excluded from the study. 
Image analysis
A systematic review of all imaging studies, includ-
ing baseline and follow-up studies, was performed 
by two radiologists with 8 and 13 years of experi-
ence in consensus. A total of 7 MRIs, 26 CTs, and 3 
FDG-PET/CT studies were analyzed. Four of the 13 
patients had MR imaging of their primary tumor at 
our institution. For these patients the location and 
size (largest dimension in two orthogonal planes) 
was documented. The T1, T2, and enhancement 
characteristics were noted. T2 images with and 
without fat saturation and STIR images were in-
FIGURE 1A. 64 year old male with slow growing extraskeletal myxoid chondrosarcoma. 
Axial T2 fat-saturated (FS) MRI demonstrates a large lobulated T2 hyperintense mass 
with T2 hypointense internal fibrous septa.
FIGURE 1B. Axial T1 fast spoiled gradient-echo (FSPGR) FS pre-contrast MRI shows 
that this tumor is isointenese to muscle on T1 weighted images. 
FIGURE 1C. Axial T1 FSPGR FS post-contrast MRI demonstrates peripherhal/septal contrast enhancement. (D). Axial contrast enhanced CT shows that 
this mass is slightly hypodense to muscle.
C DRadiol Oncol 2014; 48(3): 235-242.
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cluded when evaluating T2 characteristics of the tu-
mors. The same features were also evaluated in the 3 
patients with histologically proven local recurrence. 
Twelve patients had metastatic disease, with 
all undergoing contrast enhanced CT. Two radi-
ologists reviewed the sites and imaging features 
of metastases in consensus. The Hounsfield unit 
(HU) of the center of each primary, recurrent, and 
metastatic site was measured to determine if CT 
attenuation correlated with the classic pathologic 
description of abundant myxoid stroma. Density 
measurements were performed on lung metasta-
ses only if tumor opacity on mediastinal window 
images was greater than half the size of that seen 
on lung window images. This technique has been 
used in other studies to correlate CT attenuation 
of lung nodules with prognosis.14,15 FDG-PET/CT 
imaging was performed on three patients with 
metastatic disease who demonstrated progressive 
disease on diagnostic restaging CT scans and were 
enrolled in experimental clinical trials. On FDG-
PET/CT, the FDG avidity (standard uptake value 
[SUV]max) of the largest tumor was recorded.
Histopathologic and clinical correlation
The histology was reviewed by a single patholo-
gist from our institution with expertise in sarcoma. 
The following pathologic features were recorded: 
mitotic rate, necrosis, and tumor margin. It is im-
practical and unnecessary in clinical practice to his-
tologically confirm each metastatic site. However, 
at least one metastatic site in each of these patients 
was confirmed by biopsy. The remaining sites of 
disease were presumed to be metastatic if they 
showed unequivocal progression on imaging or if 
they showed treatment response consistent with 
the overall clinical picture. Other clinical features 
including primary presentation, treatment offered, 
recurrence or metastasis-free interval and outcome 
were also noted.
Statistical analysis
In order to study the effect of size of the primary tu-
mor on behavior of EMC, we correlated the tumor 
size (largest dimension in two orthogonal planes) 
with metastasis-free interval using Spearman cor-
relation. Since in our experience, the majority of 
EMCs occurred in the extremities, the extrem-
ity EMCs were compared with EMC in the torso 
for differences in size and metastasis-free interval 
(Mann-Whitney test). Non-parametric tests were 
used in order to minimize the effect of a few outly-
ing values. We originally intended to analyze the 
effect of size and location on recurrence-free inter-
val and survival; however, given the small number 
of patients with local recurrence and patients de-
ceased, we did not perform that analysis.
Results
Patients
The patient population consisted of 3 women and 
10 men, with a mean age of 54 years (range 29–73 
years) (Table 1). Nine patients had their primary 
tumor in the lower extremity. The site of primary 
tumor was in the pelvis for 2 patients and in the 
spine for 2 patients (Table 2). The average follow 
up interval was 40.5 months (range 7-194 months). 
One patient was lost to follow up. Three patients 
had locally recurrent disease and 12 patients had 
metastases. Three patients died during the time-
frame of the study, 1 was lost to follow up, and 9 
are still alive.
Imaging features of primary disease
The average tumor size was 9.3 cm (range 3.3‒18 
cm). All tumors were large and lobular, with no in-
ternal calcification. Four patients had MRI of the 
primary tumor. Tumors were isointense to muscle 
on T1, hyperintense to muscle on T2, and contained 
T2 hypointense internal septa. Primary tumors al-
so demonstrated peripheral/septal enhancement 
(Figure 1). Contrast enhanced CT imaging was 
FIGURE 1E. FDG-PET/CT images show no significant FDG uptake in numerous lung 
metastases. Radiol Oncol 2014; 48(3): 235-242.
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available for 2 primary tumors which were slightly 
hypodense to muscle with HU measuring 23.4 and 
30.2 (Table 3).
Local recurrence
Three patients had locally recurrent disease. The 
average time to recurrence was 52.3 months (range 
4‒81 months). Surveillance imaging varied among 
patients but generally consisted of CT imaging 
every 3‒6 months. Of the three patients with local 
recurrence, one patient had routine MRI surveil-
lance every year while the other two patients had 
MRI based on their clinical situation. One patient 
had clinical symptoms that lead to an MRI while 
the other patient has local recurrence that was de-
tected on surveillance CT. Of note, MRI in this case 
revealed more extensive tumor burden which was 
underestimated on CT. In all cases, there was no 
statistically significant correlation between the size 
of the original tumor and recurrent disease. 
The appearance of recurrent disease was simi-
lar to that of primary disease. Masses were lobular, 
extremely T2 hyperintense, isointense on T1, and 
usually demonstrated T2 hypointense internal sep-
ta and peripheral/septal enhancement. The three 
patients also had contrast enhanced CT imaging of 
their local recurrence. Two patients had recurrent 
tumor that was isodense to muscle. The HU of the 
other patient’s recurrent tumor was 72.4. However, 
this tumor was immediately adjacent to a femoral 
prosthesis and measurement was compromised by 
substantial streak artifact. The density of this tu-
mor was likely closer to that of the patient’s meta-
static disease which measured 32.4 to 39.7 HU.
Metastatic disease
Twelve patients developed metastases. The aver-
age time between initial presentation and devel-
opment of metastatic disease was 7 months (range 
0‒93 months). Imaging follow up for patients var-
TABLE 1. Clinical features of patients with extraskeletal myxoid chondrosarcoma
Case Age Gender Primary 
site
Tumor 
size (cm)
Time to recurrence
(months)
Time from diagnosis to 
metastases (months)
Survival after 
diagnosis (months)
1 68 M Thigh 3.3 25
2 67 M Foot 4.2 40
3 53 M Thigh 7 50
4 43 M Thigh 9.5 0
5 29 M Calf 12 10 18
6 68 F Thigh 13 0
7 64 M Thigh 14 0 81
8 44 F Thigh 15 0
9 73 M Thigh 18 81 93 143
10 32 M Spine 4.3
11 59 F Spine 6.6 0
12 54 M Pelvis 8 4 4
13 62 M Pelvis 10 72 50  
F = female; M = male 
FIGURE 2. 54 year old male with extraskeletal myxoid chondrosarcoma. FDG-PET/CT 
imaging shows mild peripheral FDG uptake with an standard uptake value (SUV)max 
of 2.8 in a patient with mildly dense tumor burden. Radiol Oncol 2014; 48(3): 235-242.
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TABLE 2. Location of metastatic disease
Site Total number of patients
Lung  
Pleura/parenchyma 12
Bone 3
Abdominal/pelvic nodes 2
Soft tissues 2
Mediastinal nodes 1
Peritoneum 1
Abdominal/pelvic viscera 0
FIGURE 3A. 29 year old male with unusually aggressive extraskeletal 
myxoid chondrosarcoma presenting in the calf. Axial FDG-PET/
CT demonstrating significant FDG uptake (SUVmax 7.4) in bone 
metastasis in a patient with high density tumor burden.
FIGURE 3B. Axial FDG-PET/CT also showing significant FDG 
uptake in pulmonary and pleural metastases.
ied but generally consisted of CT staging every 3 to 
6 months. There was no correlation between size of 
the primary tumor and metastasis free interval. All 
twelve patients had lung metastases, making it the 
most frequent site of tumor metastasis regardless 
of original tumor site (Table 2). Bone was the next 
most common site, though far less likely with only 
3 patients developing osseous metastases. Osseous 
metastases were lytic in all three, and in 2 of the 
3 patients were associated with a soft tissue com-
ponent. Abdominal or pelvic viscera, such as liver, 
spleen, pancreas, and kidneys, were not involved. 
Metastatic lesions demonstrated HU ranging from 
8.2 to 82.9, with median of 31.2 HU. No correlation 
was seen between tumor size and metastasis-free 
interval. No significant difference was seen in tu-
mor size or metastasis-free interval between EMC 
in the extremity or torso.
FDG-PET/CT imaging was performed on three 
patients with metastases who demonstrated pro-
gressive disease on diagnostic restaging CT scans 
and were enrolled in experimental clinical trials. 
One patient had non-FDG avid disease and anoth-
er patient had mild peripheral tumor uptake with 
an SUVmax 2.8 (Figure 1 and 2). The third patient 
had intense FDG avid disease with an SUVmax of 
7.4 (Figure 3). During the time period of this study, 
2 of these 3 patients died. The patient with intense 
FDG uptake was also the patient with solid appear-
ing metastatic disease (82.9 HU). This patient died 
within 18 months of diagnosis. The patient with no 
significant FDG uptake had low density metastases 
on contrast enhanced CT (33.6 HU), which is more 
typical of myxoid tumors, and died 81 months af-
ter diagnosis. The patient with mildly FDG avid 
disease had metastatic tumor measuring 41.0 HU. 
This patient is still a live, approximately 43 months 
after diagnosis. Table 4 summarizes the SUVmax, CT 
density, and survival after diagnosis for the three 
patients who obtained FDG-PET/CT imaging. 
FIGURE 3C. FDG PET study on October 2008 demonstrating tumor burden. (D). FDG PET 
study on December 2008 shows rapid evolution of tumor burden from October 2008. 
C DRadiol Oncol 2014; 48(3): 235-242.
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with surgical resection. The 2 patients who did not 
receive surgery had pulmonary metastases at the 
time of presentation. Five patients received chemo-
therapy and radiation as additional treatment at 
some point during their illness. Two received only 
additional radiation therapy after surgery and 1 
received only additional chemotherapy. As men-
tioned, 1 patient demonstrated particularly aggres-
sive tumor. This patient had a wide local resection 
of his primary tumor and later went on to receive 
radiation and chemotherapy. 
Discussion
Extraskeletal myxoid chondrosarcoma is a rare ne-
oplasm. The radiology literature about this entity 
is sparse, and to our knowledge this is one of the 
first studies to report the entire imaging spectrum 
of primary, recurrent, and metastatic disease of pa-
tients from a single institution. 
Extraskeletal myxoid chondrosarcoma predom-
inantly occurs in the soft tissues of the lower ex-
tremities and has a prolonged clinical course.13 The 
mean age of the cohort was 54 years (range 29–73 
years), similar to other studies.2,13 Approximately 
54% of patients in this cohort had primary disease 
in the thigh, which is consistent with prior report-
ed studies. The average tumor size was 9.3 cm with 
a range of 3.3 to 18 cm (Table 1).
On MRI, all primary tumors were hyperintense 
on T2, isointense to muscle on T1, and demonstrat-
ed peripheral/septal enhancement. These results 
TABLE 3. Hounsfield units of primary, recurrent, and metastatic tumor burden
Case Primary Recurrence Mediastinal 
nodes
Abdominal 
nodes Retroperitoneum Lung Soft tissue Bone
1 29.4 25.7
2 11.0
3 20.3
4 14.0
5 61.1 82.9 56.4
6   8.2
7 23.4 21.2 33.6 21.4 26.8
9 72.4 39.7 34.8 32.4
11 30.2 38.1 20.0 53.2
12 41.0 37.3
13 32.2 16.9
Hounsfield units were measured in the center of the lesion on contrast enhanced CTs. If patients had multiple studies, the study with the largest tumor 
burden was used. For patients with multiple lung or nodal metastases, the average Hounsfield unit is provided. One patient had lung metastases that 
were too small to accurately measure. 
TABLE 4. Density and standard uptake value (SUV)max of patients with PET imaging
  Survival after 
diagnosis SUVmax HU
Case 7 81 0 33.6
Case 12 2.8 41.0
Case 5 18 7.4 82.9
Highest Hounsfield unit (HU) measured including primary, recurrent, or metastatic tumor 
burden on contrast enhanced CT. 
Histopathologic correlation
Eleven of the thirteen patients had wide local ex-
cision as part of their treatment. The two patients 
who were not treated surgically had pulmonary 
metastases at the time of presentation. Three tu-
mors demonstrated necrosis. Mitotic rate was gen-
erally low, ranging from 1‒4 per 10 high-power 
fields. Of note, the patient with intense FDG uptake 
showed high grade tumor. Histologically, tumor 
cells were arranged in a reticular architecture with 
abundant myxoid stroma. Tumors were composed 
of bland and uniform spindle cells with hyperchro-
matic nuclei and delicate eosinophilic cytoplasm. 
Fluorescence in situ hybridization (FISH) using 
break-apart probes showed EWSR1 rearrangement 
at 22q12 in one case (Figure 4).
Clinical correlation
Three patients died during the course of this study. 
All but 2 of the 13 patients were initially treated Radiol Oncol 2014; 48(3): 235-242.
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differ from another study in which the T1 charac-
teristics were predominantly intermediate or high 
relative to muscle.6 This could reflect some degree 
of variability in the T1 appearance of the tumor. 
FIGURE 4A. 62 year old male with extraskeletal myxoid 
chondrosarcoma in the pelvis. Axial contrast enhanced CT 
showing locally recurrent tumor in the left perineum that is 
isointense to muscle.
FIGURE 4B. Numerous, large lung metastases.
FIGURE 4C. The tumor shows a lobulated appearance. 
FIGURE 4D. The tumor cells are arranged in a reticular 
architecture with abundant myxoid stroma.
FIGURE 4E. The tumor is composed of bland and uniform spindle 
cells with hyperchromatic nuclei and delicate eosinophilic 
cytoplasm.
FIGURE 4F. Fluorescence in situ hybridization (FISH) using break-
apart probes shows EWSR1 rearrangement at 22q12. Note the 
separation of the red (centromeric) and green (telomeric) 
probes
High T2 signal and heterogeneous enhancement 
are similar findings to previously reported MRI 
characteristics of primary tumor.6 On contrast 
enhanced CT, primary tumors were isodense to 
slightly hypodense to muscle with no internal cal-
cification. Local recurrence occurred in three pa-
tients with similar imaging features to the primary 
tumor. Given that EMC can have a similar density 
to muscle on CT while appearing extremely hyper-Radiol Oncol 2014; 48(3): 235-242.
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intense on T2 weighted MRI, MRI seems to be the 
best modality for detecting primary disease and lo-
cal recurrence.
Twelve patients had metastatic disease, with 
all 12 having at least lung metastases. Bone and 
nodal involvement was present in several patients. 
Interestingly, abdominal visceral involvement 
was not seen. These findings are similar to a prior 
study which showed that lung metastases were the 
most common site of metastatic disease.2 The total 
number of patients in our study with metastases 
was higher than a previous study which reported 
13 out of 42 patients either presenting with or de-
veloping metastases during an average follow up 
period of 7.4 years.13 The higher level of metastases 
in our cohort could be due to the fact that our in-
stitution is a tertiary care hospital that is a referral 
center for complicated cases. 
Three out of 13 patients died in this study popu-
lation. This corresponds to the low grade nature of 
EMC and previous reports of an overall survival 
of 100% at 5 years and 88% at 10 years.13 One of 
the patients who died had a particularly aggressive 
form of the disease. This patient was the young-
est at 29 years and only lived 18 months after di-
agnosis. Imaging findings in this patient were 
somewhat different than the other patients. On 
CT, the patient’s tumor was more solid appearing 
(82.9 HU) than that of other patients. It was also 
FDG avid with an SUVmax of 7.4. Two other patients 
had FDG-PET/CT imaging. Their tumors were ei-
ther not FDG avid or only mildly so. Their disease 
burden demonstrated lower Hounsfield unit val-
ues and a more protracted clinical course which 
is typical of EMC. This raises the possibility that 
tumor density on contrast enhanced CT and FDG-
PET could provide useful prognostic information. 
FDG-PET uptake has already been shown to have 
prognostic significance in other types of conven-
tional chondrosarcoma.16 This is not to suggest that 
FDG-PET/CT imaging should be done in all cases 
of EMC, but rather that it may be useful in patients 
where there is concern about tumor aggressiveness 
and in patients with tumor burden that is hyper-
dense to muscle on contrast enhanced CT. 
Our study has several limitations. First, the sam-
ple size was small due to the rarity of the disease, 
particularly in a single institution. Second, some 
patients presented to our institution after initial 
imaging and treatment were performed at an out-
side hospital. Imaging of the primary tumor was 
therefore not available for some of these cases. 
Despite the limitations of this study, our findings 
raise the hypothesis that tumor density on contrast 
enhanced CT and FDG-PET uptake may correlate 
with clinical behavior. This requires further explo-
ration. Furthermore, although it is a rare tumor, 
EMC should be included in one’s differential for ex-
traskeletal soft tissues masses which display little to 
no internal calcification, peripheral/septal enhance-
ment, and increased T2 prolongation. Imaging of 
the chest is also crucial given the frequency of lung 
metastases in patients with this tumor. 
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